Altimmune, a late clinical-stage biopharmaceutical company, focuses on its lead candidate pemvidutide, progressing through Phase 2b results toward planned Phase 3 trials for liver and metabolic diseases. Despite no product revenues yet, the company shows modest revenue growth from grants and contracts, sustained operating losses narrowing year-over-year, and relies on a multi-tranche debt facility plus recent equity raises to fund extensive R&D programs. With a solid liquidity buffer exceeding $270 million at year-end 2025, Altimmune balances development milestones against cash burn and market uncertainties, including legal risks tied to regulatory disclosures. Investor attention should center on trial enrollment updates and capital allocation decisions in the near term.